BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16136166)

  • 1. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
    Entz-Werle N; Suciu S; van der Werff ten Bosch J; Vilmer E; Bertrand Y; Benoit Y; Margueritte G; Plouvier E; Boutard P; Vandecruys E; Ferster A; Lutz P; Uyttebroeck A; Hoyoux C; Thyss A; Rialland X; Norton L; Pages MP; Philippe N; Otten J; Behar C;
    Leukemia; 2005 Dec; 19(12):2072-81. PubMed ID: 16136166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Reguerre Y; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Méchinaud F; Lejars O; Piguet C; Couillaud G; Pautard B; Landman-Parker J; Thuret I; Aladjidi N; Baruchel A; Leverger G;
    Leukemia; 2005 Dec; 19(12):2082-9. PubMed ID: 16121218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
    Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
    Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
    Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
    Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).
    Oosterveld M; Suciu S; Verhoef G; Labar B; Belhabri A; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Zittoun R; Hess U; Anak O; Beeldens F; Willemze R; de Witte T
    Leukemia; 2003 May; 17(5):859-68. PubMed ID: 12750698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.
    Gibson BE; Wheatley K; Hann IM; Stevens RF; Webb D; Hills RK; De Graaf SS; Harrison CJ
    Leukemia; 2005 Dec; 19(12):2130-8. PubMed ID: 16304572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
    Dluzniewska A; Balwierz W; Armata J; Balcerska A; Chybicka A; Kowalczyk J; Matysiak M; Ochocka M; Radwanska U; Rokicka-Milewska R; Sonta-Jakimczyk D; Wachowiak J; Wysocki M
    Leukemia; 2005 Dec; 19(12):2117-24. PubMed ID: 16107894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].
    Creutzig U; Bender-Götze C; Klingebiel T; Ebell W; Friedrich W; Stollmann-Gibbels B; Schmidt H; Suttorp M; Gratwohl A; Heyen P
    Klin Padiatr; 1992; 204(4):246-52. PubMed ID: 1518260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
    Reiffers J; Stoppa AM; Attal M; Michallet M; Marit G; Blaise D; Huguet F; Corront B; Cony-Makhoul P; Gastaut JA; Laurent G; Molina L; Broustet A; Maraninchi D; Pris J; Hollard D; Faberes C
    Leukemia; 1996 Dec; 10(12):1874-82. PubMed ID: 8946925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.
    Keating S; Suciu S; de Witte T; Mandelli F; Willemze R; Resegotti L; Broccia G; Thaler J; Labar B; Damasio E; Bizzi B; Rotoli B; Vekhoff A; Muus P; Petti MC; Dardenne M; Solbu G; Vegna ML; Zittoun RA
    Bone Marrow Transplant; 1996 Jun; 17(6):993-1001. PubMed ID: 8807105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
    Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
    N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.
    Smith FO; Alonzo TA; Gerbing RB; Woods WG; Arceci RJ;
    Leukemia; 2005 Dec; 19(12):2054-62. PubMed ID: 16136168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.